Table 2.

Top 25 Active FDA-Approved Drugs from Primary Screen.

No.	SMDC ID	Name	HPV Infection IC50 (μM)	293FT Cell Viability IC50 (μM)
1	131248	Floxuridine	<0.007	>15
2	735569	Ancitabine	<0.007	5
3	131375	Bleomycin	<0.007	2
4	255720	Etoposide	0.01	1
5	735623	Amsacrine	0.01	1
6	915004	Clofarabine	0.02	2
7	285708	Cladribine	0.05	4
8	285803	Irinotecan	0.06	3
9	735553	Thiostrepton	0.1	3
10	131546	Trifluridine	0.1	>15
11	131324	Hycanthone	0.1	6
12	756738	Clofarabine	0.4	2
13	285957	Rubitecan	0.8	>15
14	285779	Oxaliplatin	1	8
15	130676	Fluorouracil	1	13
16	131779	Trichlormethine	1	9
17	255957	Securinine	2	4
18	757032	Tolonium chloride	2	4
19	130032	Ciclopirox	2	8
20	130690	Mechlorethamine	2	>15
21	130651	Pentamidine	2	9
22	757019	Bronopol	3	7
23	285650	Fluorodeoxyuridine	4	13
24	131711	Doxifluridine	5	16
25	41379	Ondansetron	5	>15
26	130726	Nortriptyline	6	>15

The table displays the diverse drug classifications identified. A subset of the top 25 drugs from the primary screen of 1906 was compiled to select a smaller set of drugs for secondary stock dose–response activity. Securinine (no. 17) displayed IC₅₀ = 2 μM HPV infection compared with IC₅₀ = 4 μM cell viability and pentamidine (no. 21) displayed IC₅₀ = 2 μM HPV infection compared with IC₅₀ = 9 μM cell viability in 293FT cells.